Metabolon’s Quantose IR Test to Feature at 2012 American Diabetes Association Meeting

Metabolon, Inc. has announced that the clinical utility of the company’s lead diagnostic product Quantose™ IR will be featured in five poster presentations at the 72nd Annual Scientific Sessions of the American Diabetes Association (ADA) being held June 8-12 in Philadelphia.

Quantose IR is a fasting blood test to measure insulin resistance (IR). The test measures levels of three novel non-glycemic biomarkers and insulin to detect prediabetes earlier and with greater sensitivity than traditional glycemic markers such as glucose and Hemoglobin A1C.

“This marks our fourth consecutive ADA annual meeting and our expanded presence this year reflects our Company’s continued focus on developing diagnostic tests related to metabolic disease,” said John Ryals, President and CEO of Metabolon. “As insulin resistance is known to precede Type 2 diabetes by up to 10 years, Quantose IR offers clinicians a tool for identifying patients at greatest risk for disease progression long before glycemic markers show evidence of dysregulation. Clinicians seeking to intervene in this high-risk group will be provided unique pathophysiological insight helpful in tailoring treatments to individual patients. Our Quantose IR test also provides a useful therapeutic monitoring tool to complement traditional markers in gauging treatment effectiveness due to its non-glycemic markers tracking so closely with changing insulin sensitivity.”

Metabolon has discovered a number of significant biochemical markers indicative of risk for Type 2 diabetes. These markers are currently being incorporated in the development of the Quantose™ series of diagnostic products. The first-generation Quantose™ product is a diagnostic test for better identifying high-risk, insulin-resistant patients and predicting their risk of progression to Type 2 diabetes, above and beyond traditional risk factors and glycemic tests. The validated test is currently being offered in Metabolon’s CLIA laboratory as Investigational Use Only.

The poster presentations will discuss Metabolon’s ongoing research and development efforts associated with Quantose IR. For more information about Metabolon, please click on the ‘request information’ tab below, or follow the company website link.